NMS-812 is under clinical development by Nerviano Medical Sciences and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NMS-812’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NMS-812 overview

NMS-812 is under development for the treatment of relapsed and refractory multiple myeloma. It is administered as capsule through oral route and it acts by targeting PRKR like endoplasmic reticulum kinase (PERK) and general control non-repressed 2 (GCN2).

Nerviano Medical Sciences overview

Nerviano Medical Sciences (NMS), a subsidiary of NMS Group SpA, is involved in discovering and developing small molecule NCEs (new chemical entities) for oncology indications. It is primarily focusing on developing inhibitors including encorafenib, for melanoma and colorectal cancer; entrectinib for relapsed/refractory tumors and onvansertib for AML (acute myeloid leukemia) and solid tumors. Its pipeline also includes milciclib and NMS-153 for hepatocellular carcinoma (HCC); NMS-088 for acute myeloid leukemia; and NMS-293 for breast, ovarian, prostate and pancreatic tumors. The company utilizes KINASE and ADC platform technologies to carry out the research and development of its novel treatments. NMS is headquartered in Milan, Lombardy, Italy.

For a complete picture of NMS-812’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.